Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: Results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers  by Low, Jenny G.H. et al.
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Methods:  A  novel,  fully  bacterially  produced  recombinant  virus-like  particle  (VLP) based  inﬂuenza  vac-
cine (gH1-Qbeta)  against  A/California/07/2009(H1N1)  was  tested  in  a  double-blind,  randomized  phase
I clinical  trial  at  two  clinical  sites  in  Singapore.  The  trial  evaluated  the immunogenicity  and  safety  of
gH1-Qbeta  in the presence  or absence  of alhydrogel  adjuvant.  Healthy  adult  volunteers  with  no  or  low
pre-existing  immunity  against  A/California/07/2009  (H1N1)  were  randomized  to  receive  two  intramus-
cular  injections  21 days  apart, with  100  g  vaccine,  containing  42  g  hemagglutinin  antigen.  Antibody
responses  were  measured  before  and  21  days  after  each  immunization  by hemagglutination  inhibition
(HAI)  assays.  The  primary  endpoint  was  seroconversion  on  Day  42, deﬁned  as  percentage  of  subjects
which  reach  a HAI  titer ≥40  or achieve  an at least  4-fold  rise  in HAI  titer  (with  pre-existing  immunity).
The  co-secondary  endpoints  were  safety  and  seroconversion  on  Day  21.
Results: A  total  of  84  Asian  volunteers  were  enrolled  in  this  study  and  randomized  to receive  the  adju-
vanted  (n  = 43)  or the  non-adjuvanted  (n = 41)  vaccine.  Of those,  43  and  37  respectively  (95%)  completedsians
nﬂuenza
andemic
the  study.  There  were  no  deaths  or serious  adverse  events  reported  during  this  trial.  A total  of  535  adverse
events  occurred  during  treatment  with  49.5%  local solicited  symptoms,  of mostly  (76.4%)  mild  severity.
The most  common  treatment-related  systemic  symptom  was  fatigue.  The  non-adjuvanted  vaccine  met  all
primary  and  secondary  endpoints  and  showed  seroconversion  in  62.2%  and  70.3%  of participants  respec-
tively  on Day  21 and  Day  42. While  the  adjuvanted  vaccine  showed  an  increased  seroconversion  from
25.5%  (Day  21)  to  51.2%  (Day 42),  it did  not  meet  the immunogenicity  endpoint.
Abbreviations: HAI, hemagglutination inhibition; HA, hemagglutinin; VLP, virus-like particle; RNA, ribonucleic acid; cGMP, current good manufacturing practices;
DS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SE-HPLC, size exclusion high-performance liquid chromatography; MHC, major histocompatibility
omplex; AE, adverse event; MedDRA, medical dictionary for regulatory authorities.
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264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Conclusion:  In summary,  non-adjuvanted  gH1-Qbeta  showed  similar  antibody  mediated  immunogenicity
and a comparable  safety  proﬁle  in healthy  humans  to  commercially  available  vaccines.  These  results
warrant  the consideration  of  this  VLP  vaccine  platform  for the  vaccination  against  inﬂuenza  infection
(HSA  CTC1300092).
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. Introduction
In June 2009; the World Health Organization declared a pan-
emic with the emergence of the A/California/04/2009 (H1N1)
nﬂuenza strain which quickly spread all over the world [1,2]. A
unctional vaccine produced by traditional methods took 5 months
o become available and the total global production was below one
illion doses [3]; partly due to the egg-based vaccine production
echnology with limited yields and time consuming production [4].
he recent development to produce inﬂuenza vaccines in mam-
alian cell culture has removed the full dependence on eggs but
imitations remain: the yields are rather low and viruses still
eed to be processed in a similar time-consuming manner as for
he egg-grown vaccines [4]. Advances in molecular biology and
ecombinant technologies have opened avenues for the design
nd development of new inﬂuenza vaccines which attempt to
ddress these limitations. These technologies include subunit vac-
ines based on recombinant baculovirus expressed hemagglutinin
HA) in insect cells [5,6]; bacterially produced globular HA domain
used to ﬂagellin [7,8]; nucleic acid based vaccines [9,10]; viro-
omes (liposomes containing inﬂuenza surface antigens) [11] and
ecombinant virus-like particles (VLPs) produced in plant- or insect
ells [12,13]. Meanwhile; with several VLP-based blockbuster vac-
ines against human papillomavirus and hepatitis on the market;
he VLP technology has proven its great beneﬁts [14,15]. The suc-
ess of these novel technologies is also highlighted by the efforts
nderway to bring VLP-based inﬂuenza vaccines to the market;
urrently at different stages of clinical development [13,16]. While
hese approaches hold great promise toward a more rapidly scal-
ble inﬂuenza vaccine; most are still reliant on production in
ukaryotic cells and cannot approach the yields obtained for recom-
inant prokaryotic expression systems.
Here we describe the testing of a novel VLP-based inﬂuenza
accine, gH1-Qbeta, produced in Escherichia coli. The platform
sed from Cytos (Schlieren, Switzerland) is based on RNA bacterio-
hage Qbeta (Leviviridae) VLPs and has been shown to be capable of
nducing strong antibody responses in clinical trials for therapeutic
accines [17]. More than 700 subjects have previously been treated
ith this VLP at doses up to 900 g. Qbeta coupled to nicotine,
ngiotensin II or interleukin 1 was used as therapeutic vaccine
gainst nicotine dependence, high ambulatory blood pressure or
iabetes, respectively, and displayed good safety and tolerability
17–20]. Each VLP consists of 180 copies of the Qbeta coat protein.
hese VLPs are highly stable, non-infectious and cannot replicate.
mportantly, since humans are not naturally infected by Qbeta,
hey do not have pre-existing immunity to the VLP. The gH1-Qbeta
accine tested here consists of the globular head domain (gH1)
f hemagglutinin (HA) from the pandemic A/California/07/2009
H1N1) inﬂuenza strain, expressed in E. coli, chemically linked
o Qbeta VLPs. The resulting conjugated vaccine displays gH1 in
 highly ordered and repetitive fashion on the surface of Qbeta
LPs. Single strand RNA (from the recombinant E. coli production
train RB791 [21] and therefore without any infectious potential)
ontained within the VLPs, acts as a built-in adjuvant for the vac-
ine, shown to promote MHC  class II presentation of the antigenic
pitopes [22] and at the same time acts as a Toll-like receptor
TLR) 7/8 agonist to boost Th1 responses [23]. The vaccine has been
reviously described [24] and was shown in pre-clinical studieshed  by Elsevier  Ltd. This  is  an  open  access  article  under  the  CC BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
to protect mice and ferrets from inﬂuenza infection and to induce
both protective antibodies and, unlike conventional inﬂuenza
vaccines, potent T-cell responses [25]. Importantly, this vaccine
showed excellent cross-protection against heavily drifted strains
in mice [24]. This is the ﬁrst clinical trial with a VLP-based inﬂuenza
HA vaccine that is produced entirely in bacteria. Qbeta-VLPs can
be stockpiled and only the antigen needs to be produced and
conjugated to the carrier. Hence, this vaccine could address the
shortcomings of current approved vaccines, particularly in cases
of an emerging pandemic. The clinical assessment of safety and
immunogenicity of gH1-Qbeta is thus an important step toward
a proof of concept and here we  present its assessment in healthy
adult volunteers of Asian origin.
2. Materials and methods
2.1. Vaccine production
The antigen sequence was derived from hemagglutinin of
the inﬂuenza A virus strain A/California/07/2009 (H1N1), Gen-
Bank accession number: ACP41953.1 (amino acids 49-325) and
C-terminally extended with a linker sequence (GGGCG) to a total
of 281 amino acids. Puriﬁcation and refolding of gH proteins has
been described [24]. The cGMP manufacture of recombinant gH1
was performed in a 100 L fermenter at Biomeva GmbH (Germany)
and was formulated to contain a ﬁnal concentration of 10% glycerol
at 1.9 mg/mL, stored at ≤−65 ◦C.
The cGMP production of the recombinant VLP in E. coli
RB791 was performed in an 800 L glycerol fed batch at
Lonza AG (Switzerland) [26]. Puriﬁed Qbeta was  stored at
3 mg/mL  between −60 ◦C and −90 ◦C. To manufacture the drug
substance gH1 was cross-linked to Qbeta using succinimyl 6-
[(maleimidopropionamido)-hexanoate] and formulated in PBS at
a concentration of 1.9 mg/mL  containing 0.01% Tween-20. Purity
and integrity of the VLP were conﬁrmed by SDS-PAGE and size-
exclusion HPLC respectively, for details see Supplemental Material
and Methods.
For clinical use gH1-Qbeta (batch 12036) was  formulated in
20 mM sodium phosphate, 150 mM sodium chloride, 1.5% (v/v)
glycerol, 0.01% (v/v) Tween-20 and water for injection (pH 7.2) and
ﬁlled and ﬁnished by Symbiosis Pharmaceutical Services Ltd. (Scot-
land, UK). It was supplied in 2 mL  single-use vials, ﬁlled with 350 L
at a concentration of 0.4 mg/mL  (determined by protein content)
and stored at ≤−65 ◦C. The purity and the integrity of the VLP were
assessed by scanning densitometry after SDS-PAGE and SE-HPLC,
respectively. The coupling density of gH1-Qbeta was  determined by
SDS-PAGE as 31% and endotoxin levels (according to Ph. Eur.2.9.19)
were <0.6 EU/mg protein.
Other components of the vaccine (adjuvant, diluent) were
provided in the same 2 mL  single use vials. The adjuvant (2%
Alhydrogel® EP-grade, Brenntag-Biosector, Denmark) adjusted
with diluent (phosphate buffered saline solution containing 0.01%
Tween-20 (v/v) and 1.5% (v/v) glycerol, pH 7.2) to a ﬁnal alu-kept refrigerated (2–8 ◦C). Diluent vials were ﬁlled with 300 L
and stored at −20 ◦C. Immediately prior to injection the vaccine
(250 L) was  mixed with equal volumes of alhydrogel or diluent
cine 3
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n an empty, 2 mL  sterile vial provided, and 500 L were injected
n the deltoid muscle using a masked syringe with a 25G, 16 mm
eedle.
.2. Study design
This was a double-blinded, 1:1 randomized Phase 1 healthy vol-
nteer study conducted at two sites in Singapore. The study was
esigned to assess the safety, tolerability and immunogenicity of
he vaccine in healthy adults with no or low pre-existing immunity
o A/California/07/2009 (H1N1). Subjects received two intramus-
ular injections, of 100 g vaccine (42 g HA) per dose, 21 days
part, either non-adjuvanted or adjuvanted with 2% alhydrogel, in
 total volume of 500 L per injection. A total of 84 subjects were
andomized to the two treatment arms. Study personnel and par-
icipants were blinded to the treatment allocation, except for the
ndependent statistician from the Singapore Clinical Research Insti-
ute (SCRI), generating the randomization list and the unblinded
linical research coordinator, mixing the vaccine with alhydrogel
r diluent prior to injection.
.3. Subjects and study procedures
Study approval was obtained from the Singapore Health Sci-
nces Authority (HSA) and the Centralized Institutional Review
oard (CIRB Ref: 2012/906/E) and the study was  performed in
greement with the International Conference on Harmonisation
uidelines on Good Clinical Practices, laws and regulatory require-
ents in Singapore and monitored by SCRI. A written informed
onsent was obtained from each subject prior to screening. Subjects
ere ﬁrst enrolled on May  16, 2013 with the last visit on August 2,
013.
Participants, between 21 and 64 years of age, with satisfac-
ory baseline medical assessment and laboratory values within the
ormal ranges were eligible. Exclusion criteria were presence of
cute infection during 14 days preceding the ﬁrst vaccination, a
emperature ≥38 ◦C at the date of the ﬁrst vaccination, and the
eceipt of immunoglobulins or blood products within 9 months
rior to enrolment or during the study. Additional exclusion cri-
eria were receipt of seasonal inﬂuenza vaccine in the past 2 years,
r any licensed vaccine within 30 days prior to the ﬁrst injec-
ion or HAI titers >1:40 at screening. Concomitant medications
except other vaccines) were not restricted. Women  of child-
earing potential had to have a negative pregnancy test at each
isit.
.4. Safety assessments
Safety of the vaccine was a co-secondary endpoint, with the
ollowing factors assessed: vital signs: (blood pressure, pulse, res-
iratory rates and body temperature) at all visits (Days 0, 21 and 42)
nd on vaccination days pre- and 60 min  post-vaccination, hema-
ology and blood biochemistry at all visits, solicited and unsolicited
ocal/systemic events (symptom diaries) 21 days following each
accination. All adverse events (AEs) were coded according to the
edDRA adverse event dictionary (version 12.1) [27] and graded
or severity using the FDA guidance document for the toxicity scale
or healthy adult and adolescent volunteers enrolled in preventive
accine clinical trials [28].
.5. Immunogenicity assessmentsScreening samples were assessed using standard, non-validated
AI assays at Duke-NUS Graduate Medical School. All further
mmunogenicity assessments on sera of recruited volunteers
rom baseline (Day 0), Day 21 and Day 42 were performed2 (2014) 5041–5048 5043
on blinded samples, under GLP conditions, using validated HAI
assays at Southern Research Institute (Birmingham, AL). In
addition to A/California/07/2009 (H1N1) cross-reactive immuno-
genicity against A/Brisbane/10/10 (H1N1) and A/Georgia/01/13
(H1N1) was  tested. All virus strains were purchased from
the Centers for Disease Control and Prevention (CDC; Atlanta,
GA).
2.6. Statistical methods
An unblinded research coordinator randomly assigned subjects
1:1 to the adjuvanted or the non-adjuvanted group. A computer-
generated list (SAS® software, NC, USA) with randomly permutated
block sizes of 4 and 6 was provided by SCRI. A sample size of 32
subjects per arm was required to achieve the FDA criterion for
seroconversion with a power of 80%, assuming an incidence of 65%
[29]. To compensate for 20% drop-outs 40 subjects per arm were
planned. The study was  not powered to achieve the FDA criterion
for seroprotection.
The primary endpoint was seroconversion against
A/California/07/2009 (H1N1) by HAI on Day 42, deﬁned as
either a pre-vaccination HAI titer <10 and a post vaccination
HAI titer ≥40, or a pre-vaccination HAI titer ≥10 and minimum
four-fold rise in post-vaccination HAI titer. The co-secondary
endpoint (with safety) was  seroconversion on Day  21. In addition,
geometric mean titers (GMT) and the percentage of subjects
achieving seroprotection (HAI titer ≥40), were calculated, the
latter only for subjects with baseline HAI titers <40. Geometric
mean titer fold rise (GMR) was calculated and GMT  and GMR
were compared between groups on log-transformed HAI titers
using the two-sample t-test [30–32]. The 95% CIs of GMT  and GMR
were constructed by exponential transformation of related 95% CIs
based on the log-transformed HAI titer data. Values shown are for
the modiﬁed Intention-to-treat (ITT) population, not including two
subjects that withdrew consent prior to receiving the ﬁrst dose.
AEs and severe AEs were summarized by treatment group with
each subject counted once per AE category with the highest severity
of treatment emergent AE (Day 0-Day 42).
3. Results
3.1. Study subjects
Of 156 healthy volunteers consented and screened, 84 were
randomized to the treatment groups and scheduled to receive adju-
vanted (n = 43) or non-adjuvanted (n = 41) vaccine. Two subjects
from the non-adjuvanted group withdrew consent prior to their
ﬁrst vaccination and two  more withdrew consent after they had
received the ﬁrst dose. A total of 43 (adjuvanted) and 37 (non-
adjuvanted) subjects completed the study (Fig. 1).
The mean age of enrolled subjects was 39.5 years with 61% of
them being male. All were of Asian ethnicity with a Chinese major-
ity (79%, Table 1).
3.2. Safety
Eighty-nine percent of subjects experienced at least one AE dur-
ing the study (Day 0-Day 42). No serious/life threatening AEs were
reported. A total of 11 (13.4%) subjects developed at least one severe
AE (grade 3). In total there were 535 AEs reported (278 in the adju-
vanted and 257 in the non-adjuvanted arm), of which 265 (49.5%)
were local (Table 2). The most frequent local symptoms were pain
and muscle ache, followed by limitation of movement in their vacci-
nated arm and itch (Fig. 2A). The most common treatment-related
non-local symptom was  fatigue, followed by myalgia, headache,
oropharyngeal pain and rhinorrhea (Fig. 2B). Most AEs (76.4%)
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Randomized(n=84)
Assessed for eligibility (n=156) 
Excluded (n=72) 
-HAI ter > 40 (n=34) 
-Unsasfactory medical assessment (n=19) 
-Not willing to comply with protocol (n=10) 
-Acute infecon in the preceding 14 days (n=7) 
-Others (n=2) 
ITT analyses of immunogenicity  (n=43) 
Excluded from ITT (n=0) 
Safety analysis (n=43)
Excluded from safety analysis (n =0) 
Allocated to Adjuvanted (n=43) 
Received 1st dose (n=43) 
Did not receive 1st dose (n=0)  
Allocated to Non-Adjuvanted (n=41) 
Received 1st dose (n=39) 
Did not receive 1st dose (n=2)  
 -   2 withdrew consent  
Received 2nd dose (n=43) 
Did not receive 2nd dose (n=0)  
Received 2nd dose (n=37) 
Did not receive 2nd dose (n=2)  
 -   2 withdrew consent  
Completed study (n=43) 
Did not complete study (n=0)  
Completed study (n=37) 
Did not complete study (n=0)  
 ITT analyses of immunogenicit y (n=39) 
Excluded from ITT (n=2) 
- 2 did not receive any dose 
Safety analysis (n=39) 
Excluded from safety analysis (n=2) 
- 2 did not receive any dose 
ﬂow a
w
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1Fig. 1. Subject 
ere mild; with 15.3% moderate and 8.2% severe. All AEs were
esolved by day 42 except three: cataract in one subject; and two
ymptoms (tiredness and running nose from allergic rhinitis) in a
econd subject, considered unrelated to gH1-Qbeta and still on-
oing at the last visits. No modiﬁcation was made to the study drug
dministration because of any AE. The AEs proﬁle was  comparable
etween the adjuvanted and the non-adjuvanted group (Table 2
nd Fig. 2).
able 1
emographic characteristics of subjects.
Characteristic Adjuvanted (n = 43) 
Age (years) n = 43 
Mean (SD) 37.7 (9.5) 
Median (IQR) 36.0 (14.0) 
Min,  Max  21, 60 
Gender  n (%)
Male 28 (65.1) 
Female 15 (34.9) 
Ethnicity n (%)
Chinese 34 (79.1) 
Malay 5 (11.6) 
Indian 3 (7.0) 
Others1 1 (2.3) 
Javanese, Burmese and Pakistani.nd disposition.
3.3. Immunogenicity
The immunogenicity of the vaccine with and without alhydro-
gel adjuvant was assessed by HAI titers against A/California/7/2009
(H1N1) at Day 42. The proportion of seroconverted subjects after
two doses of vaccine is shown in Table 3. In the adjuvanted
group, 22/43 (51.2%, 95% CI: 36.8 to 65.4%) and in the non-
adjuvanted group 26/37 (70.3%, 95% CI: 54.2 to 82.5%) achieved
Non-adjuvanted (n = 39) Total (n = 82)
n = 39 n = 82
41.6 (10.8) 39.5 (10.3)
42.0 (16.0) 39.0 (13.0)
21, 63 21, 63
22 (56.4) 50 (61.0)
17 (43.6) 32 (39.0)
31 (79.5) 65 (79.3)
2 (5.1) 7 (8.5)
4 (10.3) 7 (8.5)
2 (5.1) 3 (3.7)
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Table  2
Summary of adverse events (treated population).
Number of subjects (%) Number of events
Adjuvanted (n = 43) Non-adjuvanted (n = 39) Total (n = 82) Adjuvanted Non-adjuvanted Total
Subjects with at least one AE 38 (88.4) 35 (89.7) 73 (89.0) NA NA NA
Local  symptoms 35 (81.4) 35 (89.7) 70 (85.4) 136 129 265
Systemic symptoms 30 (69.8) 25 (64.1) 55 (67.1) 142 128 270
Severity1
Grade 1 (Mild) 38 (88.4) 34 (87.2) 72 (87.8) 226 183 409
Grade 2 (Moderate) 11 (25.6) 14 (35.9) 25 (30.5) 35 47 82
Grade 3 (Severe) 6 (14.0) 5 (12.8) 11 (13.4) 17 27 44
Outcome2
Recovered 38 (88.4) 35 (89.7) 73 (89.0) 276 256 532
Recovered with sequalae 0 0 0 0 0 0
Not  recovered 1 (2.3) 1 (2.6) 2 (2.4) 2 1 3
Relationship to IP
Not related 7 (16.3) 6 (15.4) 13 (15.9) 12 17 29
Unlikely related 12 (27.9) 7 (17.9) 19 (23.2) 41 16 57
Possibly related 20 (46.5) 20 (51.3) 40 (48.8) 73 86 159
Probably related 23 (53.5) 20 (51.3) 43 (52.4) 62 50 112
Deﬁnitely related 33 (76.7) 33 (84.6) 66 (80.5) 90 88 178
Treatment given for AE 7 (16.3) 6 (15.4) 13 (15.9) 13 12 25
1 There was  no AE of Grade 4 (potentially life threatening) severity.
2 There was  no AE that lead to death.
Fig. 2. Adverse events: (A) Incidence of solicited local AEs that occurred after the ﬁrst and before the second vaccination (left panel) and during the 21 days following the
second vaccination (right panel). (B) Systemic (non-solicited) AEs occurring in ≥5% of subjects after the ﬁrst and the second vaccination are shown in the left and right hand
panels,  respectively.
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Table 3
Summary of antibody mediated immunogenicity.
Non-adjuvanted (n = 39) Adjuvanted (n = 43)
Day 0 Day 21 Day 42 Day 0 Day 21 Day 42
A/California/07/2009 (H1N1)
GMT  (95% CI) 5.8 (4.9–7.0) 61.0 (35.9–103.5) 70.2 (43.2–114.1) 5.5 (5.0–6.0) 15.0 (10.4–21.4) 33.2 (23.1–47.8)
Seroconversion (95% CI) (%) NA 62.2 (46.1–75.9) 70.3 (54.2–82.5) NA 25.6 (14.9–40.2) 51.2 (36.8–65.4)
Seroprotection (95% CI) (%) NA 66.7 (50.3–79.8) 75.0 (58.9–86.2) NA 30.2 (18.6–45.1) 53.5 (38.9–67.5)
GMR  (95% CI) NA 10.3 (6.0–17.7) 11.9 (7.1–19.8) NA 2.7 (2.0–3.8) 6.1 (4.2–8.8)
A/Brisbane/10/2010 (H1N1)
GMT  (95% CI) 6.6 (5.2–8.5) 76.3 (40.4–144.2) 90.4 (52.9–154.3) 6.7 (5.6–8.1) 25.3 (16.3–39.1) 54.3 (36.2–81.6)
Seroconversion (95% CI) (%) NA 64.9 (48.8–78.2) 73.0 (57.0–84.6) NA 41.9 (28.4–56.7) 62.8 (47.9–75.6)
Seroprotection (95% CI) (%) NA 65.7 (49.2–79.2) 74.3 (57.9–85.8) NA 45.2 (31.2–60.1) 71.4 (56.4–82.8)
GMR  (95% CI) NA 11.3 (6.1–20.9) 13.4 (7.9–22.8) NA 3.8 (2.6–5.4) 8.1 (5.5–11.8)
A/Georgia/01/2013 (H1N1)
GMT  (95% CI) 6.2 (5.1–7.7) 51.0 (27.0–96.3) 66.3 (37.3–118.0) 6.1 (5.3–7.0) 17.7 (11.5–27.3) 41.6 (27.0–64.2)
Seroconversion (95% CI) (%) NA 56.8 (40.9–71.3) 64.9 (48.8–78.2) NA 34.9 (22.4–49.8) 58.1 (43.3–71.6)
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GMR  (95% CI) NA 8.2 (4.4–15.0) 1
eroconversion. Hence, only the non-adjuvanted group met  the FDA
riterion of a ≥40% lower bound CI for seroconversion. An increase
n the percentage of subjects with seroconversion between Day
1 and Day 42 was observed in both groups after boosting. The
ercentage of subjects with seroconversion was lower in the adju-
anted group than in the non-adjuvanted group on both days. Of the
9 subjects who had baseline HAI titers <40 and HAI titers available
n Day 21 and Day 42, 13/43 (30.2%) in the adjuvanted group, and
4/36 (66.7%) in the non-adjuvant group (p = 0.002) showed sero-
rotection against the strain A/California/7/2009 (H1N1) on Day
1 (Table 3). The GMT  was signiﬁcantly higher (p = 0.013) in the
on-adjuvanted group (GMT = 70.2) than in the adjuvanted group
GMT = 33.2).
In addition cross-reactivity of the induced antibodies was  eval-
ated against two drifted inﬂuenza strains, A/Brisbane/10/2010
H1N1) and A/Georgia/01/2013 (H1N1). The immunogenicity
gainst both strains was similar to that demonstrated for
/California/7/2009. The seroconversion rates following two doses
f the non-adjuvanted vaccine were 73.0% (95% CI: 57.0 to 84.6%)
nd 64.9% (95% CI: 48.8 to 78.2%) for the A/Brisbane/10/2010
H1N1) and A/Georgia/01/2013 strain, respectively, (Table 3) satis-
ying the FDA criterion of a 40% lower bound CI for seroconversion.
. Discussion
In this clinical study the bacterially produced pandemic
nﬂuenza vaccine candidate gH1-Qbeta proved to be well-tolerated
nd immunogenic in healthy volunteers of Asian ethnicity.
A systematic review of 40 studies with commercially licensed,
ingle dose inactivated inﬂuenza vaccines performed between
990 and 2006 showed a seroconversion rate of 72% for inﬂuenza
/H1N1 strains (95% CI: 66% to 78%) with a large variation between
ndividual studies (ranging from 20 to 100%) [33]. Results for non-
djuvanted gH1-Qbeta were comparable, therefore supporting the
fﬁcacy of gH1-Qbeta. The antigen dose required (42 g HA) was
igher than the 5 g shown to be sufﬁcient to achieve serocon-
ersion with the baculovirus-produced VLP vaccine (Novavax Inc.)
gainst the same inﬂuenza strain [16]. However, in contrast to the
ovavax vaccine and egg-based inﬂuenza vaccines the antigen of
H1-Qbeta is based on the globular HA domain only, without lipid
i-layer. The dose (100 g) was chosen based on ferret efﬁcacy
tudies [25] and isn’t necessarily the lowest efﬁcacious dose. An
dditional clinical study will be required to establish the lowest
ose inducing seroconversion.
In a large randomized controlled trial, comparing an intrader-
al  with an intramuscular inﬂuenza vaccine in adults [34], local
nd systemic reactions were demonstrated with the intramuscular.3–79.8) NA 38.1 (25.0–53.2) 61.9 (46.8–75.0)
0–18.6) NA 2.9 (2.0–4.2) 6.9 (4.6–10.1)
vaccine in 66.3% and 47.9% of subjects, respectively. In our study
with the intramuscular gh1-Qbeta we observed a higher incidence
of local reactions, especially injection site pain, but a lower inci-
dence of most systemic reactions as compared to the intramuscular
inﬂuenza vaccine described by Arnou et al. [34]. Overall, adverse
events observed were similar in type and range to those described
in other inﬂuenza vaccine studies [7,16,35].
In this study gH1-Qbeta alone induced higher HAI titer against
A/California/7/2009 (H1N1) than in the presence of alhydrogel
adjuvant. This is in line with ﬁndings with other inﬂuenza vaccines
where aluminum based adjuvants did not improve or even reduced
the immunogenicity of inﬂuenza vaccines [36–41], however, these
ﬁndings were not expected after preclinical efﬁcacy models in mice
and ferrets where alhydrogel increased HAI titers or had a neu-
tral effect, respectively [25]. Further studies would be required to
ensure that no changes in antigen structure occurred after adsorp-
tion to alhydrogel although a research group investigating the effect
of aluminum adsorption on antigen structure have not found any
changes in the six proteins they have investigated [42,43].
Of interest is the cross-reactivity of the induced antibodies
observed against two drifted inﬂuenza strains: A/Brisbane/10/2010
(H1N1) and A/Georgia/01/2013(H1N1). All H1N1 strains since the
early phase of the pandemic in 2009 have acquired three muta-
tions (P100S, S220T and I338V) in the HA domain compared to
A/California/7/2009 (H1N1) without leading to reduced antigenic-
ity of these strains. Although A/Brisbane/10/2010 (H1N1) which
acquired additional two mutations (E391K and N142D) compared
to A/California/7/2009 (H1N1), was  still antigenically similar to
A/California/7/2009 (H1N1) using ferret antisera, HAI GMTs against
this strain were 53% lower in human sera of subjects vaccinated
with Fluvax® (CSL Limited, Australia), a marketed ﬂu vaccine
against A/California/7/2009 (H1N1), than against the cognate virus
A/California/7/2009 (H1N1) [44,45]. In contrast, after vaccination
with gH1-Qbeta, HAI titers against A/Brisbane/10/2010 (H1N1)
were comparable to those achieved against A/California/7/2009
(H1N1), indicating a more persistent cross-reactive immunogenic-
ity compared to the egg-based Fluvax®.
Likewise, A/Georgia/01/2013 (H1N1), a representative of a
genetically drifted H1N1 strain from early 2013 (FluSurver tool
[http://ﬂusurver.bii.a-star.edu.sg]) which has already acquired a
total of 11 mutations in the HA domain (P100S, D114N, K180Q,
S202T, S220T, A273T, K300E, I338V, E391K, S468N, E516K) com-
pared to the original A/California/07/2009 (H1N1) was  recognized
similarly as the cognate A/California/07/2009 (H1N1) by the
induced antibodies as determined by HAI assay. The fact that
this vaccine against A/California/07/2009 (H1N1) shows simi-
lar reactivity to two different drifted strains with 5 and 11
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utations, respectively, underscores the quality of the immune
esponse induced and suggests that this vaccine may  be protective
ver several ﬂu seasons conﬁrming the excellent cross-protection
ound with this vaccine in a mouse model for inﬂuenza infection
24].
In summary, the study presented here shows, for the ﬁrst time,
hat a fully bacterially produced VLP inﬂuenza vaccine is able to
nduce a strong anti-viral antibody response of high quality and
herefore vaccines based on the Qbeta platform are a potential
pproach for responding to an inﬂuenza pandemic. However, to
evelop this technology for wider use it would be important to
stablish to what extent this vaccine technology can be used in indi-
iduals repeatedly immunized with Qbeta vaccines and whether
 B-cell response against the Qbeta component would interfere
ith subsequent immunizations with different antigens. Once this
as been established this novel technology may  serve as a new
ool in our armamentarium to ﬁght future pandemics and seasonal
nﬂuenza epidemics.
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